Next Article in Journal
Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Previous Article in Journal
Harnessing the Power of Nanocarriers to Exploit the Tumor Microenvironment for Enhanced Cancer Therapy
 
 
Communication

Article Versions Notes

Pharmaceuticals 2025, 18(5), 747; https://doi.org/10.3390/ph18050747
Action Date Notes Link
article xml file uploaded 19 May 2025 12:11 CEST Original file -
article xml uploaded. 19 May 2025 12:11 CEST Update -
article pdf uploaded. 19 May 2025 12:11 CEST Version of Record https://www.mdpi.com/1424-8247/18/5/747/pdf-vor
article html file updated 19 May 2025 12:14 CEST Original file -
article html file updated 19 May 2025 12:51 CEST Update -
article xml file uploaded 21 May 2025 10:22 CEST Update -
article xml uploaded. 21 May 2025 10:22 CEST Update -
article pdf uploaded. 21 May 2025 10:22 CEST Updated version of record https://www.mdpi.com/1424-8247/18/5/747/pdf-vor
article html file updated 21 May 2025 10:24 CEST Update -
article xml file uploaded 22 May 2025 06:38 CEST Update -
article xml uploaded. 22 May 2025 06:38 CEST Update -
article pdf uploaded. 22 May 2025 06:38 CEST Updated version of record https://www.mdpi.com/1424-8247/18/5/747/pdf-vor
article html file updated 22 May 2025 06:41 CEST Update -
article pdf uploaded. 4 June 2025 11:45 CEST Minor correction https://www.mdpi.com/1424-8247/18/5/747/pdf
article xml uploaded. 4 June 2025 11:45 CEST Minor correction https://www.mdpi.com/1424-8247/18/5/747/xml
article html file updated 4 June 2025 11:48 CEST Update https://www.mdpi.com/1424-8247/18/5/747/html
Back to TopTop